Fabry Disease Race: Former CDER Official Siegel Interprets Committee Votes
Executive Summary
During a Jan. 15 conference call sponsored by the Schwab Washington Research Group, former Office of Therapeutics Review & Research Director Jay Siegel, MD, gave his interpretation of the outcome of the advisory committee reviews of the two pending Fabry disease therapies, Genzyme's Fabrazyme and TKT's Replagal. Here are his comments, as transcribed by "The Pink Sheet." Coverage of the committee meetings can be found on pp. 12-16.